Melanoma Institute Australia launches free e-learning education portal
20 June 2018
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment to ensure best practice and equity of care for melanoma patients around the country.
The new online education portal is designed for healthcare professionals including specialists, dermatologists, GPs and nurses. It provides accredited videos and comprehensive training modules relating to the rapidly changing melanoma diagnostic and treatment landscape.
Melanoma Institute Australia Conjoint Medical Director, Professor Georgina Long, said the e-learning portal would ultimately improve melanoma patient care and outcomes within Australia and internationally.
“Our new education portal will be practice changing for healthcare professionals, particularly those who do not normally specialise in diagnosing and treating melanoma,” Professor Long said. “It gives them access to training modules covering best practice in diagnosing and managing melanoma, as well as translating world-leading research into clinical knowledge to ultimately improve patient outcomes.”
MIA Conjoint Medical Director, Professor Richard Scolyer, added, “We’re excited to bring together the collective expertise from MIA, which is the world’s largest research and treatment institute with a single focus on melanoma. The portal will ensure healthcare professionals have free 24/7 access to the latest advances in melanoma clinical practice and research, regardless of where they are located. This will benefit melanoma patients all over the world, and ultimately, save lives.” he said.
New content will be added to the site regularly and registered healthcare professionals can earn accreditation points. Healthcare professionals are invited to access the free site by registering at melanomaeducation.org.au
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.
Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research.
We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role.
Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category.
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.
We have a winner!
Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
If you would like to download a bib for your Melanoma March, we have a selection for you to choose from, print and bring along with you on the day.
Manly Melanoma March has changed to a new location.
We did a short Q&A with two sisters who are raising funds for Melanoma March after sadly losing their mother in 2009. This is their second march and they have shared with us their fundraising tips.
We want to share with you what your valuable Melanoma March donation and fundraising goes towards and our Research Director, Graham Mann explains the national research project the funds will be going towards.
Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) clinical trial has recruited its first patient.
You are invited to provide comments for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC will consider the registration of the anti-PD1 drug, Keytruda (pembrolizumab) at the next meeting in March.
Melanoma patient Joel Allsop was congratulated today on completing his participation in the international surgical clinical trial, known as MSLT-II. He was the first person in the world to complete the 10 years of follow-up for this trial.
Melanoma Institute Australia (MIA) has officially launched the 2015 ‘Melanoma March’ initiative in Melbourne.